Moxidectin: an oral treatment for human onchocerciasis

References

• Basáñez MG, Pion SDS, Churcher TS, et al. River blindness: a success story under threat? PLoS Med. 2006;3(9):e371.
   PubMed Web of Science ®Google Scholar
• Colebunders R, Basáñez MG, Siling K, et al. From river blindness control to elimination: bridge over troubled water. Infect Dis Poverty. 2018;7(1):21.
   PubMedGoogle Scholar
• Sauerbrey M, Rakers LJ, Richards FO Jr. Progress toward elimination of onchocerciasis in the Americas. Int Health. 2018;10(Suppl 1):i71–i78.
   PubMedGoogle Scholar
• Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859–1922.
   PubMed Web of Science ®Google Scholar
• Fobi G, Yameogo L, Noma M, et al. Managing the fight against onchocerciasis in Africa: APOC experience. PLoS Negl Trop Dis. 2015;9(5):e0003542.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases – a roadmap for implementation; 2012 [cited 2020 June 27]. Available from: https://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf
   Google Scholar
• African Programme for Onchocerciasis Control. Final Communiqué of the 18th session of the joint action forum (JAF) of APOC. Bujumbura, Burundi; 2012 Dec 11–13 [cited 2020 June 27]. Available from: https://www.who.int/apoc/about/structure/jaf/Final_Communique_JAF_18_English_final_with_annexes.pdf?ua=1
   Google Scholar
• World Health Organization. WHO launches global consultations for a new roadmap on neglected tropical diseases; 2019 [cited 2020 June 27]. Available from: https://www.who.int/neglected_diseases/news/WHO-launches-global-consultations-for-new-NTD-Roadmap/en/; https://www.who.int/neglected_diseases/news/NTD-Roadmap-targets-2021-2030.pdf?ua=1
   Google Scholar
• Basáñez MG, Pion SDS, Boakes E, et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(5):310–322.
   PubMed Web of Science ®Google Scholar
• Walker M, Pion SDS, Fang H, et al. The macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness. Clin Infect Dis. 2017;65(12):2026–2034.
   PubMed Web of Science ®Google Scholar
• Dadzie Y, Amazigo UV, Boatin BA, et al. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes. Infect Dis Poverty. 2018;7(1):63.
   PubMedGoogle Scholar
• Katabarwa MN, Walsh F, Habomugisha P, et al. Transmission of onchocerciasis in Wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. J Parasitol Res. 2012;748540:2012.
   Google Scholar
• Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40–8.
   PubMedGoogle Scholar
• Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist. 2016;6(3):272–286.
   PubMed Web of Science ®Google Scholar
• FDA. US Food & Drug Administration. Drug approval package: moxidectin; 2018 [cited 2020 June 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000TOC.cfm; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf
   Google Scholar
• Awadzi K, Opoku NO, Attah SK, et al. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.
   PubMed Web of Science ®Google Scholar
• Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207–1216.
   PubMed Web of Science ®Google Scholar
• Verdú JR, Cortez V, Martinez-Pinna J, et al. First assessment of the comparative toxicity of ivermectin and moxidectin in adult dung beetles: sub-lethal symptoms and pre-lethal consequences. Sci Rep. 2018;8(1):14885.
   PubMedGoogle Scholar
• Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol. 2003;43(10):1108–1115.
   PubMed Web of Science ®Google Scholar
• Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582–589.
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Parks V, Patat A, et al. Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32–37.
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Parks V, Chalon S, et al. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial. Am J Trop Med Hyg. 2012;86(1):122–125.
   PubMed Web of Science ®Google Scholar
• González Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10(1):42–46.
   PubMed Web of Science ®Google Scholar
• Prichard R, Ménez C, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134–153.
   PubMed Web of Science ®Google Scholar
• Dupuy J, Escudero E, Eeckhoutte C, et al. In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species. Vet Res Commun. 2001;25(5):345–354.
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Parks V, Wagner F, et al. Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(2):151–157.
   PubMed Web of Science ®Google Scholar
• Hennessy DR, Alvinerie MR. Pharmacokinetics of the macrocyclic lactones: conventional wisdom and new paradigms. In: Vercruysse J, Rew RS, editors. Macrocyclic lactones in antiparasitic therapy. Wallingford, Oxon, UK: CAB International; 2002. p. 97–123.
   Google Scholar
• Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother. 2011;55(11):5200.
   PubMed Web of Science ®Google Scholar
• Lespine A, Martin S, Dupuy J, et al. Interaction of macrocyclic lactones with P-glycoprotein: structure–affinity relationship. Eur J Pharm Sci. 2007;30(1):84–94.
   PubMed Web of Science ®Google Scholar
• Griffin J, Fletcher N, Clemence R, et al. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther. 2005;28(3):257–265.
   PubMed Web of Science ®Google Scholar
• Kiki-Mvouaka S, Menez C, Borin C, et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos. 2010;38(4):573–580.
   PubMed Web of Science ®Google Scholar
• Perez M, Blazquez AG, Real R, et al. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact. 2009;180(1):106–112.
   PubMed Web of Science ®Google Scholar
• Janko C, Geyer J. Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin. J Vet Pharmacol Ther. 2013;36(3):275–284.
   PubMed Web of Science ®Google Scholar
• Geyer J, Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones. Curr Pharm Biotechnol. 2012;13(6):969–986.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sheps JA, Ling V, et al. Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J Mol Biol. 2004;344(2):409–417.
   PubMed Web of Science ®Google Scholar
• Godoy P, Lian J, Beech RN, et al. Haemonchus contortus P-glycoprotein-2: in situ localisation and characterisation of macrocyclic lactone transport. Int J Parasitol. 2015;45(1):85–93.
   PubMed Web of Science ®Google Scholar
• Janssen IJI, Krücken J, Demeler J, et al. Genetic variants and increased expression of Parascaris equorum P-glycoprotein-11 in populations with decreased ivermectin susceptibility. PLoS One. 2013;8(4):e61635.
   PubMed Web of Science ®Google Scholar
• Janssen IJI, Krücken J, Demeler J, et al. Transgenically expressed Parascaris P-glycoprotein-11 can modulate ivermectin susceptibility in Caenorhabditis elegans. Int J Parasitol Drugs Drug Resist. 2015;5(2):44–47.
   PubMed Web of Science ®Google Scholar
• Ardelli BF, Prichard RK. Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin. Vet Parasitol. 2013;191(3–4):264–275.
   PubMed Web of Science ®Google Scholar
• Maté L, Ballent M, Cantón C, et al. Assessment of P-glycoprotein gene expression in adult stage of Haemonchus contortus in vivo exposed to ivermectin. Vet Parasitol. 2018;264:1–7.
   PubMed Web of Science ®Google Scholar
• Lloberas M, Alvarez L, Entrocasso C, et al. Measurement of ivermectin concentrations in target worms and host gastrointestinal tissues: influence of the route of administration on the activity against resistant Haemonchus contortus in lambs. Exp Parasitol. 2012;131(3):304–309.
   PubMed Web of Science ®Google Scholar
• Lespine A, Ménez C, Bourguinat C, et al. P-glycoproteins and other ABC transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2012;2:58–75.
   PubMed Web of Science ®Google Scholar
• Knab J, Darge K, Büttner DW. Immunohistological studies on macrophages in lymph nodes of onchocerciasis patients after treatment with ivermectin. Trop Med Int Health. 1997;2(12):1156–1169.
   PubMed Web of Science ®Google Scholar
• Moreno Y, Nabhan JF, Solomon J, et al. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc Natl Acad Sci U S A. 2010;107(46):20120–20125.
   PubMed Web of Science ®Google Scholar
• Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.
   PubMed Web of Science ®Google Scholar
• Alley ES, Plaisier AP, Boatin BA, et al. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans R Soc Trop Med Hyg. 1994;88(5):581–584.
   PubMed Web of Science ®Google Scholar
• Plaisier AP, Alley ES, Boatin BA, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the onchocerciasis control programme in West Africa. J Infect Dis. 1995;172(1):204–210.
   PubMed Web of Science ®Google Scholar
• Pion SDS, Nana-Djeunga HC, Kamgno J, et al. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multi-treated population from Cameroon. PLoS Negl Trop Dis. 2013;7:e2084.
   PubMed Web of Science ®Google Scholar
• Bottomley C, Isham V, Collins RC, et al. Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Parasitology. 2008;135(13):1571–1581.
   PubMed Web of Science ®Google Scholar
• Gardon J, Boussinesq M, Kamgno J, et al. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360(9328):203–210.
   PubMed Web of Science ®Google Scholar
• Campillo JT, Chesnais CB, Pion SDS, et al. Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually. Parasit Vectors. 2020;13(1):258.
   PubMed Web of Science ®Google Scholar
• Collins RC, Gonzales-Peralta C, Castro J, et al. Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities. Am J Trop Med Hyg. 1992;47(2):156–169.
   PubMed Web of Science ®Google Scholar
• Njongmeta LM, Nfon CK, Gilbert J, et al. Cattle protected from onchocerciasis by ivermectin are highly susceptible to infection after drug withdrawal. Int J Parasitol. 2004;34(9):1069–1074.
   PubMed Web of Science ®Google Scholar
• Wolstenholme AJ, Maclean MJ, Coates R, et al. How do the macrocyclic lactones kill filarial nematode larvae? Invert Neurosci. 2016;16(3):7.
   PubMed Web of Science ®Google Scholar
• Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature. 2011;474(7349):54–60.
   PubMed Web of Science ®Google Scholar
• Wolstenholme A, Rogers A. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology. 2005;131(S1):S85–S95.
   PubMedGoogle Scholar
• Li BW, Rush AC, Weil GJ. High level expression of a glutamate-gated chloride channel gene in reproductive tissues of Brugia malayi may explain the sterilizing effect of ivermectin on filarial worms. Int J Parasitol Drugs Drug Resist. 2014;4(2):71–76.
   PubMed Web of Science ®Google Scholar
• Verma M, Pathak M, Shahab M, et al. Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models. Folia Parasitol (Praha). 2014;61(6):561–570.
   PubMed Web of Science ®Google Scholar
• Njue AI, Hayashi J, Kinne L, et al. Mutations in the extracellular domains of glutamate-gated chloride channel α3 and β subunits from ivermectin-resistant Cooperia oncophora affect agonist sensitivity. J Neurochem. 2004;89(5):1137–1147.
   PubMed Web of Science ®Google Scholar
• Forrester SG, Beech RN, Prichard RK. Agonist enhancement of macrocyclic lactone activity at a glutamate-gated chloride channel subunit from Haemonchus contortus. Biochem Pharmacol. 2004;67(6):1019–1024.
   PubMed Web of Science ®Google Scholar
• Storey B, Marcellino C, Miller M, et al. Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: ‘The Worminator’. Int J Parasitol Drugs Drug Resist. 2014;4(3):233–243.
   PubMed Web of Science ®Google Scholar
• Lallemand E, Lespine A, Alvinerie M, et al. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration. J Vet Pharmacol Ther. 2007;30(5):375–380.
   PubMed Web of Science ®Google Scholar
• Awadzi K, Attah SK, Addy ET, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98(4):359–370.
   PubMed Web of Science ®Google Scholar
• Frempong KK, Walker M, Cheke RA, et al. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness? Clin Infect Dis. 2016;62(11):1338–1347.
   PubMed Web of Science ®Google Scholar
• Doyle SR, Bourguinat C, Nana-Djeunga HC, et al. Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Negl Trop Dis. 2017;11(7):e0005816.
   PubMed Web of Science ®Google Scholar
• Churcher TS, Pion SDS, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl Acad Sci U S A. 2009;106(39):16716–16721.
   PubMed Web of Science ®Google Scholar
• Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69–83.
   PubMed Web of Science ®Google Scholar
• Doyle SR, Illingworth CJR, Laing R, et al. Population genomic and evolutionary modelling analyses reveal a single major QTL for ivermectin drug resistance in the pathogenic nematode, Haemonchus contortus. BMC Genomics. 2019;20(1):218.
   PubMedGoogle Scholar
• Hodgkinson JE, Kaplan RM, Kenyon F, et al. Refugia and anthelmintic resistance: concepts and challenges. Int J Parasitol Drugs Drug Resist. 2019;10:51–57.
   PubMed Web of Science ®Google Scholar
• Brody T. Clinical trials. Second edition. Study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Academic Press, Elsevier; 2016.
   Google Scholar
• Francis H, Awadzi K, Ottesen E. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg. 1985;34(3):529–536.
   PubMed Web of Science ®Google Scholar
• Gardon J, Gardon-Wendel N. Demanga-Ngangue, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18–22.
   PubMed Web of Science ®Google Scholar
• Herrick JA, Legrand F, Gounoue R, et al. Posttreatment reactions after single-dose diethylcarbamazine or ivermectin in subjects with Loa loa infection. Clin Infect Dis. 2017;64(8):1017–1025.
   PubMed Web of Science ®Google Scholar
• Katabarwa MN, Eyamba A, Nwane P, et al. Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the West region of Cameroon. J Parasitol Res. 2013;420928:2013.
   Google Scholar
• Eisenbarth A, Achukwi MD, Renz A. Ongoing transmission of Onchocerca volvulus after 25 years of annual ivermectin mass treatments in the Vina du Nord River Valley, in North Cameroon. PLoS Negl Trop Dis. 2016;10(2):e0004392.
   PubMed Web of Science ®Google Scholar
• Komlan K, Vossberg PS, Gantin RG, et al. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin. PLoS Negl Trop Dis. 2018;12(3):e0006312.
   PubMed Web of Science ®Google Scholar
• Duamor CT, Datchoua-Poutcheu FR, Ndongmo WPC, et al. Programmatic factors associated with the limited impact of Community-Directed Treatment with Ivermectin to control onchocerciasis in three drainage basins of South West Cameroon. PLoS Negl Trop Dis. 2017;11(11):e0005966.
   PubMed Web of Science ®Google Scholar
• Brieger WR, Okeibunor JC, Abiose AO, et al. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors. 2011;4(1):1.
   PubMedGoogle Scholar
• Osue HO. Field-based evidence of single and few doses of annual ivermectin treatment efficacy in eliminating skin microfilaria load after a decade of intervention. Ethiop J Health Sci. 2017;27(2):129–138.
   PubMed Web of Science ®Google Scholar
• Wanji S, Kengne-Ouafo JA, Esum ME, et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors. 2015;8(1):667.
   PubMedGoogle Scholar
• Kamga GR, Dissak-Delon FN, Nana-Djeunga HC, et al. Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon. Parasit Vectors. 2018;11(1):356.
   PubMedGoogle Scholar
• Turner HC, Churcher TS, Walker M, et al. Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. PLoS Negl Trop Dis. 2013;7(4):e2169.
   PubMed Web of Science ®Google Scholar
• Stolk WA, Walker M, Coffeng LE, et al. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors. 2015;8(1):552.
   PubMedGoogle Scholar
• Prost A, Hervouet JP, Thylefors B. Les niveaux d’endémicité dans l’onchocercose. Bull World Health Organ. 1979;57(4):655–662.
   PubMedGoogle Scholar
• Katabarwa MN, Eyamba A, Chouaibou M, et al. Does onchocerciasis transmission take place in hypoendemic areas? A study from the North Region of Cameroon. Trop Med Int Health. 2010;15(5):645–652.
   PubMed Web of Science ®Google Scholar
• Kelly-Hope LA, Unnasch TR, Stanton MC, et al. Hypo-endemic onchocerciasis hotspots: defining areas of high risk through micro-mapping and environmental delineation. Infect Dis Poverty. 2015;4(1):36.
   PubMedGoogle Scholar
• Cantey PT, Roy SL, Boakye D, et al. Transitioning from river blindness control to elimination: steps toward stopping treatment. Int Health. 2018;10(Suppl 1):i7–13.
   PubMedGoogle Scholar
• Kamgno J, Pion SD, Chesnais CB, et al. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med. 2017;377(21):2044–2052.
   PubMed Web of Science ®Google Scholar
• Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, et al. Effect of a single standard dose (150–200 μg/kg) of ivermectin on Loa loa microfilaremia: systematic review and meta-analysis. Open Forum Infect Dis. 2019;6(4):ofz019.
   PubMed Web of Science ®Google Scholar
• Tamarozzi F, Halliday A, Gentil K, et al. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev. 2011;24(3):459–468.
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Hoerauf A, Townson S, et al. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014;141(1):119–127.
   PubMed Web of Science ®Google Scholar
• Sulaiman WAW, Kamtchum-Tatuene J, Mohamed MH, et al. Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: current perspectives. Indian J Med Res. 2019;149(6):706–714.
   PubMed Web of Science ®Google Scholar
• Walker M, Specht S, Churcher TS, et al. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin Infect Dis. 2015;60(8):1199–1207.
   PubMed Web of Science ®Google Scholar
• Albers A, Esum ME, Tendongfor N, et al. Retarded Onchocerca volvulus L1 to L3 larval development in the Simulium damnosum vector after anti-wolbachial treatment of the human host. Parasit Vectors. 2012;5:12.
   PubMed Web of Science ®Google Scholar
• Bosshardt SC, McCall JW, Coleman SU, et al. Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus). J Parasitol. 1993;79(5):775–777.
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol. 2005;60:245–284.
   PubMed Web of Science ®Google Scholar
• Turner JD, Tendongfor N, Esum M, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis. 2010;4(4):e660.
   PubMed Web of Science ®Google Scholar
• Wanji S, Tendongfor N, Nji T, et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit Vectors. 2009;2(1):39.
   PubMedGoogle Scholar
• Tamarozzi F, Tendongfor N, Enyong PA, et al. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasit Vectors. 2012;5:53.
   PubMed Web of Science ®Google Scholar
• Debrah AY, Specht S, Klarmann-Schulz U, et al. Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo-controlled, double-blind trial. Clin Infect Dis. 2015;61(4):517–526.
   PubMed Web of Science ®Google Scholar
• Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 2001;357(9266):1415–1416.
   PubMed Web of Science ®Google Scholar
• Turner HC, Walker M, Pion SDS, et al. Economic evaluations of onchocerciasis interventions: a systematic review and research needs. Trop Med Int Health. 2019;24(7):788–816.
   PubMed Web of Science ®Google Scholar
• Walker M, Churcher TS, Wanji S, et al. The cost-effectiveness of doxycycline therapy for the control of human onchocerciasis in areas coendemic with loiasis. Am J Trop Med Hyg. 2012;87(5 Suppl):144. Presented at: American Society of Tropical Medicine and Hygiene 61st Annual Meeting; 2012 November 11 –15;Atlanta.
   PubMedGoogle Scholar
• Tan KR, Magill AJ, Parise ME, et al. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011;84(4):517–531.
   PubMed Web of Science ®Google Scholar
• Gaillard T, Briolant S, Madamet M, et al. The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malar J. 2017;16(1):148.
   PubMedGoogle Scholar
• Wanji S, Nji TM, Hamill L, et al. Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol. Parasit Vectors. 2019;12(1):574.
   PubMed Web of Science ®Google Scholar
• Edwards H. Use of an individual-based onchocerciasis transmission model (EPIONCHO-IBM) to predict the impact of a doxycycline test-and-treat intervention on infection prevalence and intensity in endemic communities of south-western Cameroon. MRes Biomedical Sciences thesis, Imperial College London; 2018.
   Google Scholar
• International Standard Randomised Controlled Trials Number (ISRCTN) Registry. The efficacy of rifapentine plus moxifloxacin against onchocerciasis: a randomized, open label pilot trial. ISRCTN; 2018 [cited 2020 June 27]. DOI:10.1186/ISRCTN43697583
   Google Scholar
• Klarmann-Schulz U, Specht S, Debrah AY, et al. Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial. PLoS Negl Trop Dis. 2017;11(1):e0005156.
   PubMed Web of Science ®Google Scholar
• Aljayyoussi G, Tyrer HE, Ford L, et al. Short-course, high-dose rifampicin achieves Wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis. Sci Rep. 2017;7(1):210. Erratum in Sci Rep. 8(1),1384 (2018).
   PubMedGoogle Scholar
• Turner JD, Sharma R, Al Jayoussi G, et al. Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis. Proc Natl Acad Sci U S A. 2017;114(45):E9712–21.
   PubMed Web of Science ®Google Scholar
• Hong WD, Benayoud F, Nixon GL, et al. AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. Proc Natl Acad Sci U S A. 2019;116(4):1414–1419. .
   PubMed Web of Science ®Google Scholar
• Drugs for Neglected Diseases initiative (DNDi). R&D portfolio in review: Filaria – river blindness (2020); 2019 [cited 2020 June 27]. Available from: https://dndi.org/news/2020/filarialdiseases-riverblindness-rnd-portfolio-update/
   Google Scholar
• Taylor MJ, von Geldern TW, Ford L, et al. Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Sci Transl Med. 2019;11(483):pii: eaau2086.
   Web of Science ®Google Scholar
• Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–265.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis. National Institutes of Health; 2020 [cited 2020 June 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03876262
   Google Scholar
• US National Library of Medicine. A pharmacokinetic and safety study of moxidectin to identify an optimal dose for treatment of children 4 to 11 years. National Institutes of Health; 2019 [cited 2020 June 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03962062
   Google Scholar
• US National Library of Medicine. Clinical trial evaluating the safety and efficacy of moxidectin 2 mg ivermectin-controlled in loa loa microfilaremic patients (EOLoa). National institutes of Health; 2019 [cited 2020 June 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT04049851
   Google Scholar
• Jacob BG, Loum D, Lakwo TL, et al. Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda. PLoS Negl Trop Dis. 2018;12(8):e0006702.
   PubMed Web of Science ®Google Scholar